Phase 2 N=109 Sex Hormones and Orthostatic Tolerance
Orthostatic Intolerance
Primary: Orthostatic Tolerance — 634 mmHg*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Effect of Exercise in OI
Orthostatic Intolerance · Postural Tachycardia Syndrome
Primary: Maximal Oxygen Consumption Capacity (VO2 Max) — 27.6; 24.5 mL/kg/min
N/A N=356 Orthostatic Hypotension Treatment on Rehab Unit
Orthostatic Hypotension · Falls
Primary: Orthostatic Hypotension at Discharge — 39; 44 Participants — p=0.6
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
N/A N=341 Orthostatic Hypotension in Rehabilitation Patients
Hypotension, Orthostatic
Primary: Orthostatic Hypotension at Discharge — 96 participants
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
Phase 4 N=24 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Orthostatic Hypotension
Primary: Time to Onset of Syncope/Near Syncope While on Tilt Table — 1105.6; 1626.6 seconds — p=0.0131
Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
Phase 2 N=11 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Phase 3 N=66 Treatment of Post-SCI Hypotension
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
N/A N=13 Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Tachycardia Syndrome
Primary: Alldosterone Increase in Response to Adrenocorticotropin Hormone (ACTH). — 52.5; 57.9 nanograms/dL
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Phase 3 N=350 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 4 N=24 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
Phase 3 N=263 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
N/A N=38 Dietary Salt in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Plasma Volume — 2805; 3032; 2362; 2633 mL
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
Phase 2 N=40 Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Neurogenic Orthostatic Hypotension
Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale
N/A N=22 Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure — 19; 3 mm Hg
Phase 3 N=103 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Neurogenic Orthostatic Hypotension · Non-Diabetic Autonomic Neuropathy · Multiple System Atrophy
Primary: Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) — 0.57; 0.90 units on a scale — p=0.438
N/A N=139 Standing Cognition and Co-morbidities of POTS Evaluation
Postural Tachycardia Syndrome · Ehlers-Danlos Syndrome
Primary: Executive Function (Stroop Word-color Test) — 48; 49; 50; 58 Testing Scores
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 2 N=34 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Neurogenic Orthostatic Hypotension · Multiple System Atrophy (MSA) With Orthostatic Hypotension · Pure Autonomic Failure
Primary: Part A: Change From Time-matched Placebo in Seated Systolic Blood Pressure (SBP) — 0.2; -1.8; -3.4; -2.9 millimeter of mercury (mmHg)
Phase 2 N=20 Using Mirabegron to Increase BP in Patients With POTS
Postural Orthostatic Tachycardia Syndrome · Chronic Orthostatic Intolerance · Syncope
Primary: Blood Pressure — 101; 107; 64; 68 mmHg